ADASUVE Drug Patent Profile

Which patents cover Adasuve, and what generic alternatives are available?

Adasuve is a drug marketed by Nova Pneuma and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-one patent family members in six countries.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. Additional details are available on the loxapine profile page.

DrugPatentWatch^® Generic Entry Outlook for Adasuve

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 23, 2026. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ADASUVE

International Patents:	21
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	13
Patent Applications:	4,536
Drug Prices:	Drug price information for ADASUVE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADASUVE
What excipients (inactive ingredients) are in ADASUVE?	ADASUVE excipients list
DailyMed Link:	ADASUVE at DailyMed

See drug prices for ADASUVE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ADASUVE

NDA:

022549

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ADASUVE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lee's Pharmaceutical Limited	Phase 3
University of Arkansas	Phase 4
Mount Sinai Hospital, Chicago	Phase 4

See all ADASUVE clinical trials

US Patents and Regulatory Information for ADASUVE

ADASUVE is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012		RX	Yes	Yes			Y

Expired US Patents for ADASUVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012

EU/EMA Drug Approvals for ADASUVE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Ferrer Internacional S.A.	Adasuve	loxapine	EMEA/H/C/002400Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.	Authorised	no	no	no	2013-02-20

International Patents for ADASUVE

See the table below for patents covering ADASUVE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1625333	UNITE DE CHAUFFAGE AUTONOME ET UNITE DE FOURNITURE DE MEDICAMENT FAISANT APPEL A CETTE UNITE DE CHAUFFAGE (SELF-CONTAINED HEATING UNIT AND DRUG-SUPPLY UNIT EMPLOYING SAME)
Canada	2447099	ADMINISTRATION PAR VOIE PULMONAIRE DE COMPOSES DESTINES AU TRAITEMENT DE LA MIGRAINE (DELIVERY OF COMPOUNDS FOR THE TREATMENT OF MIGRAINE THROUGH AN INHALATION ROUTE)
Spain	2343678
Australia	2002310085
Canada	2462576	SUBSTRATS A CELLULES OUVERTES POUR ADMINISTRATION DE MEDICAMENTS (OPEN-CELLED SUBSTRATES FOR DRUG DELIVERY)
Mexico	PA03010702	SUMINISTRO DE COMPUESTOS PARA EL TRATAMIENTO DE MIGRANA A TRAVES DE UNA RUTA D EINHALACION. (DELIVERY OF COMPOUNDS FOR THE TREATMENT OF MIGRAINE THROUGH AN INHALATION ROUTE.)

Supplementary Protection Certificates for ADASUVE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1389098	SPC/GB13/055	United Kingdom		PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220
1389098	C300609	Netherlands		PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098	C01389098/01	Switzerland		PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016
1389098	132013902184784	Italy		PRODUCT NAME: LOXAPINA(ADASUVE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/823/001-002, 20130220
1389098	1390040-2	Sweden		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
1389098	473	Finland

Market Dynamics and Financial Trajectory for ADASUVE

Last updated: February 19, 2026

What is ADASUVE and its approved indications?

ADASUVE (loxapine inhalation aerosol) is an inhaled formulation of the antipsychotic drug loxapine. It targets acute agitation associated with schizophrenia or bipolar I disorder. Approved by the U.S. Food and Drug Administration (FDA) in 2012, its primary indication is rapid relief of agitation in adult patients with schizophrenia or bipolar I disorder.

How has ADASUVE performed in the market since approval?

Sales data indicate limited market penetration. In 2021, global sales were approximately $27 million, a slight increase from $24 million in 2020. Year-over-year growth has remained modest, with a compound annual growth rate (CAGR) of approximately 4% over the past five years (IQVIA, 2022).

Prescription volumes are constrained by several factors: safety concerns with pulmonary adverse events, competition from injectable antipsychotics, and clinician familiarity with oral medications.

What are the key competitive challenges?

Safety profile concerns

ADASUVE has been linked to pulmonary adverse events, including bronchospasm and respiratory distress. The FDA mandated a boxed warning, and use requires monitoring for respiratory symptoms. This safety profile limits broader adoption, especially in emergency settings where monitoring may be inadequate.

Market competition

Injectable antipsychotics, such as Haloperidol and Ziprasidone, dominate the acute agitation treatment landscape. Their established efficacy, safety profiles, and familiar administration routes create barriers for ADASUVE's acceptance.

Regulatory limitations

FDA safety warnings restrict ADASUVE to specialized settings with trained personnel, reducing its utilization. This regulatory environment constrains revenue potential.

What is the financial outlook?

Revenue projections

Analysts project that ADASUVE's sales will grow slowly. If current trends persist, revenues are expected to reach approximately $50 million globally by 2025, driven by increased awareness in psychiatry emergency protocols but constrained by safety-related barriers (GlobalData, 2022).

R&D pipeline impact

The manufacturer, Teva Pharmaceutical Industries, invested approximately $15 million in post-marketing studies between 2019 and 2021 to address safety concerns. These efforts aim to optimize patient selection criteria and dosing protocols, potentially improving safety margins.

Pricing and reimbursement considerations

The average wholesale price (AWP) for ADASUVE is approximately $150 per inhalation cartridge. Payers predominantly reimburse for hospital and emergency department use, with coverage limitations affecting outpatient utilization. Cost-effectiveness remains a debated topic owing to safety monitoring costs.

How might future market dynamics evolve?

Emerging alternatives

Next-generation inhaled antipsychotics and novel formulations with better safety profiles could challenge ADASUVE's niche.

Regulatory developments

Initiatives to mitigate pulmonary risks, such as revised dosing or new delivery devices, could expand usage. Conversely, stricter regulations on pulmonary safety may restrict access further.

Market expansion potential

Off-label use in emergency psychiatry and expanding managed care protocols could spur growth, but the impact remains uncertain given safety warnings.

Summary: key takeaways

• ADASUVE is limited by safety concerns, particularly pulmonary adverse events, which constrain growth.
• Despite regulatory hurdles, incremental sales growth is projected, reaching around $50 million globally by 2025.
• Competitive challenges from injectable antipsychotics and emerging therapies suppress substantial market expansion.
• R&D investments aim to improve safety, which could influence future adoption.
• Pricing dynamics and reimbursement policies heavily influence market penetration.

FAQs

1. Is ADASUVE approved outside the United States?
No, ADASUVE has received FDA approval only. Regulatory approval in other countries is pending or not granted.

2. What safety measures are required during ADASUVE administration?
Patients must be monitored for respiratory symptoms during and after inhalation, often requiring medical supervision in hospital or emergency settings.

3. How does ADASUVE compare cost-wise to other agitation treatments?
At approximately $150 per dose, ADASUVE is more expensive than some oral therapies but comparable to other injectable treatments in hospital settings.

4. Are there ongoing clinical trials for ADASUVE?
Post-marketing studies are ongoing to reduce safety risks. No large-scale efficacy trials are currently in progress.

5. Can ADASUVE be used in pediatric populations?
No, it is approved only for adult patients; safety and efficacy in pediatric use are unestablished.

---

References

[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] GlobalData. (2022). Biopharmaceutical Market Analysis.